Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
10 participants
INTERVENTIONAL
2025-09-30
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The ExSpiron© is a device for non-invasive monitoring of respiratory volume. The validation of this monitor in patients with ALS is the aim of this study.
The hypothesis is that the ExSpiron© delivers a valid assessment of respiratory volume in patients with ALS
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The ExSpiron© is a device for non-invasive monitoring of respiratory volume. The validation of this monitor in patients with ALS is the aim of this study.
The hypothesis is that the ExSpiron© delivers a valid assessment of respiratory volume in patients with ALS Objective: The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
Study design: This is an intervention study The validation of the ExSpiron© in patients diagnosed with ALS is done during admission on the Respiratory Care Unit (RCU) of the University Medical Center Groningen (UMCG). At daytime, tidal volume (TV) and minute volume (MV) will be measured during spontaneous breathing with the ExSpiron© simultaneously with a pneumotachometer (gold-standard). After installation of the chest pad of the ExSpiron© and the pneumotachometer, the first measurements are in sitting position. Three complete cycles of ten breaths; normal breathing, slow-deep breathing and rapid-shallow breathing, will be done. Between each cycle, a pause is allowed. After completing this breathing sequence, it is repeated in supine position. If patients are not able to perform this in supine position, because of orthopnea, an angle of 45º degree is adequate. After completing this cycle, the chest pad should be left in place and the electromyography (EMG) equipment should be installed. During the first night of admission, a full night of measurement of TV and MV will be conducted using the ExSpiron©.
Study population: 10 patients diagnosed with ALS and an indication to start NIV, \>18 years of age.
Intervention (if applicable): The ExSpiron© is a device for non-invasive monitoring of tidal volumes and minute ventilation in non-intubated patients by using a disposable chest pad.
Main study parameters/endpoints: The main endpoint is the validation of the ExSpiron© in patients diagnosed with ALS and screened positive for starting NIV.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: NIV has no known serious side effects. ALS patients differ in starting NIV is done on the RCU while patients are monitored as standard care, the ExSpiron© is not an extra risk complaints but those screened positive to start NIV are not associated with risks. The intervention product, ExSpiron© is a non-invasive monitor with a chest pad attached to the patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ExSpiron
10 patients with ALS
ExSprion
The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ExSprion
The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants diagnosed with ALS requiring NIV
* Age \> 18 of age; \< 85 years of age
* An indication to start chronic NIV, hypercapnic respiratory failure (arterial carbon dioxide PaCO2 \> 6.0 kilo pascal (kPa) measured during daytime) or orthopnoea due to diaphragm paralysis.
* Participants are able to provide feedback
* Participants that are willing to participate and are able to consent and sign the informed consent form.
Exclusion Criteria
* Clinically unstable
* Acute respiratory failure
* Participants with refractory hypotension, defined as systolic blood pressure less than 90 mmHg, despite inotropic agents
* Uncontrolled cardiac ischemia or arrhythmias
* Participants suffering from metastatic or terminal cancer
* Other comorbid disease affecting respiration (ie obstructive sleep apnea, chronic obstructive pulmonary disease)
* Participants lacking functional medical decision-making
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Wijkstra
Principal Investigator P.J. Wijkstra
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Wijkstra, prof
Role: PRINCIPAL_INVESTIGATOR
UMCG
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMCG
Identifier Type: -
Identifier Source: org_study_id